XOMA to Present at H.C. Wainwright 2nd Annual Bioconnect Investor Conference at NASDAQ
EMERYVILLE, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ:XOMA), the biotech royalty aggregator, announced today that members of its Executive Team will participate in the H.C. Wainwright 2nd Annual
XOMA Corp (XOMA) Q1 2024 Earnings: Misses Revenue Estimates, Reports Lower Net Loss
XOMA Q1 2024 GAAP EPS $(0.86) Misses $(0.81) Estimate
XOMA (NASDAQ:XOMA) reported quarterly losses of $(0.86) per share which missed the analyst consensus estimate of $(0.81) by 6.17 percent. This is a 12.24 percent increase over losses of $(0.98) per sh
Earnings Flash (XOMA) XOMA CORPORATION Reports Q1 Revenue $1.5M
07:41 AM EDT, 05/09/2024 (MT Newswires) -- Earnings Flash (XOMA) XOMA CORPORATION Reports Q1 Revenue $1.5M
10-Q: Quarterly report
XOMA 1Q Rev $1.49M >XOMA
XOMA 1Q Rev $1.49M >XOMA
XOMA 1Q Loss/Shr 86c >XOMA
XOMA 1Q Loss/Shr 86c >XOMA
XOMA Reports First Quarter 2024 Financial Results and Highlights Recent Activities
Xoma (XOMA) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
The market expects Xoma (XOMA) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended March 2024.
Xoma Has Acquired An Economic Interest In Three Women's Health Assets From Daré Bioscience For An Upfront Payment Of $22M
Organon, a global women's healthcare company, initiated XACIATO commercial activities in the fourth quarter of 2023.XOMA further expands its late-stage portfolio with synthetic royalty and milestone i
XOMA Adds Economic Interests in Three First-in-Category Assets to Its Royalty and Milestone Portfolio Including XACIATO (Clindamycin Phosphate) Vaginal Gel 2%
Organon, a global women's healthcare company, initiated XACIATO commercial activities in the fourth quarter of 2023 XOMA further expands its late-stage portfolio with synthetic royalty and milestone interests in
XOMA Initiated at Outperform by Leerink Partners
XOMA Initiated at Outperform by Leerink Partners
Leerink Partners Initiates Coverage On XOMA With Outperform Rating, Announces Price Target of $40
Leerink Partners analyst Jason Zhuang initiates coverage on XOMA (NASDAQ:XOMA) with a Outperform rating and announces Price Target of $40.
XOMA Earns $9 Million Milestone as FDA Grants Accelerated Approval to Day One's OJEMDATM (Tovorafenib) for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (PLGG)
XOMA is entitled to a mid-single digit royalty on global OJEMDA sales First and only FDA-approved type II RAF inhibitor for patients with relapsed or refractory pLGG harboring a BRAF fusion or rearrangement, or
HC Wainwright & Co. Reiterates Buy on XOMA, Maintains $74 Price Target
HC Wainwright & Co. analyst Joseph Pantginis reiterates XOMA (NASDAQ:XOMA) with a Buy and maintains $74 price target.
XOMA Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/25/2024 188.61% HC Wainwright & Co. → $74 Reiterates Buy → Buy 03/11/2024 188.61% HC Wainwright & Co. $
AnaptysBio Names Thomas Smart as CEO >ANAB
AnaptysBio Names Thomas Smart as CEO >ANAB
Press Release: Actym Therapeutics Appoints Thomas Smart as CEO
Actym Therapeutics Appoints Thomas Smart as CEO PR Newswire BERKELEY, Calif., April 24, 2024 BERKELEY, Calif., April 24, 2024 /PRNewswire/ -- Actym Therapeutics, pioneering a new drug modality to t
Day One Wins FDA Nod Brain Cancer Therapy, Ojemda
XOMA (NASDAQ:XOMA) Shareholders Have Earned a 16% CAGR Over the Last Five Years
No Data